Patents by Inventor Mary Jeanne Kallman

Mary Jeanne Kallman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions for treating pain
    Patent number: 6936601
    Abstract: The present invention provides compositions for treating pain using an atypical antipsychotic compound that is seroquel in combination with another Drug Used in the Treatment of Pain.
    Type: Grant
    Filed: August 15, 2002
    Date of Patent: August 30, 2005
    Assignee: Eli Lilly and Company
    Inventors: David Reed Helton, Harlan E. Shannon, Daniel E. Womer, Mary Jeanne Kallman
  • Method for treating pain
    Publication number: 20030013689
    Abstract: The present invention provides a method for treating pain using an atypical antipsychotic compound.
    Type: Application
    Filed: August 15, 2002
    Publication date: January 16, 2003
    Inventors: David Reed Helton, Harlan E. Shannon, Daniel E. Womer, Mary Jeanne Kallman
  • Method for treating pain
    Patent number: 6444665
    Abstract: The present invention provides a method for treating pain using an atypical antipsychotic compound.
    Type: Grant
    Filed: February 4, 2000
    Date of Patent: September 3, 2002
    Assignee: Eli Lilly and Company
    Inventors: David R. Helton, Harlan E. Shannon, Daniel E. Womer, Mary Jeanne Kallman
  • Anxiolytic agents
    Patent number: 5882671
    Abstract: The present invention provides a method of treating anxiety and related disorders using an agonist which acts at negatively coupled cAMP-linked metabotropic glutamate receptors.
    Type: Grant
    Filed: January 21, 1997
    Date of Patent: March 16, 1999
    Assignee: Eli Lilly and Company
    Inventors: David Reed Helton, Mary Jeanne Kallman, James Allen Monn, Darryle Darwin Schoepp, Joseph Patrick Tizzano
  • Excitatory amino acid receptor antagonists
    Patent number: 5717109
    Abstract: The present invention provides compounds of formula ##STR1## in which R represents an organic group, or a pharmaceutically acceptable metabolically labile ester or amide thereof, or a pharmaceutically acceptable salt thereof, which are useful as antagonists of one or more of the actions of L-glutamate at metabotropic excitatory amino acid receptors.
    Type: Grant
    Filed: July 10, 1995
    Date of Patent: February 10, 1998
    Assignee: Eli Lilly and Company
    Inventors: M. Brian Arnold, Thomas J. Bleisch, David R. Helton, Mary Jeanne Kallman, Paul L. Ornstein, Darryle D. Schoepp, Joseph P. Tizzano
  • Psychiatric agents
    Patent number: 5661184
    Abstract: The present invention provides a method of treating substance dependence disorders using an agonist which acts at negatively coupled cAMP-linked metabotropic glutamate receptors.
    Type: Grant
    Filed: June 29, 1995
    Date of Patent: August 26, 1997
    Assignee: Eli Lilly and Company
    Inventors: David R. Helton, Mary Jeanne Kallman, James A. Monn, Darryle D. Schoepp, Joseph P. Tizzano